Background The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly increasing with high risk to develop cirrhosis, hepatocellular carcinoma (HCC) and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results